Alembic Pharmaceuticals Receives USFDA Final Approval for Valganciclovir Oral Solution
Alembic Pharmaceuticals received USFDA final approval for valganciclovir oral solution 50 mg/mL.
Related stories
Granite Construction Q3 Revenue Beats Estimates
Granite Construction's third-quarter revenue beat estimates, supported by organic growth and acquisitions.
M impact | EQUITY | Oct 29, 2026, 12:43 PM UTC
Entegris Reports Higher Fiscal Q3 Adjusted Earnings and Revenue; Sets Q4 Outlook
Entegris reported higher adjusted earnings and revenue for fiscal Q3 and set its outlook for Q4.
M impact | EQUITY | Oct 29, 2026, 12:43 PM UTC
Alnylam shares fall 6.4% premarket after Q3 results
M impact | EQUITY | Oct 29, 2026, 12:43 PM UTC
Jiangsu Zhangjiagang Rural Commercial Bank Q3 Net Profit Rises 1.37%
The bank's Q3 net profit rose 1.37% year over year.
M impact | EQUITY | Oct 29, 2026, 12:43 PM UTC
Capital Securities Q3 Net Profit Falls 52.67% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:42 PM UTC
Air France Suspends Flights to and From Dubai Until Nov. 7
M impact | EQUITY | Oct 29, 2026, 12:42 PM UTC